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Purpose. To evaluate the similarities and differences between the variety of platelet-rich plasma (PRP) formulations, preparation,
and uses to try to determine the best responses for the treatment of knee osteoarthritis. Materials and Methods. A comparison
of the outcomes of randomized controlled trials (RCTs) included in the 3 most recent and high-quality meta-analyses to classify
the different studies in 2 groups (bad responders group (BRG) and very good responders group (VGRG)). Results and Discussion.
From the 19 RCTs analyzed, 7 trials were included in the VGRG and 4 in the BRG. In VGRG, 1 or 2 injections were performed in
4/7 trials, time between injections was 2 to 3 weeks in 4/5 studies with many injections, volume injected varied from 2.5 to 8mL,
and single spinning technique was used in 5/7 studies. PRP classification was Mishra 4B and PAWP2B𝛽 in 5/7 studies. The use of
PRP with leukocytes is only found in the BRG. Conclusion. There is a lack of standardization in PRP preparation technique for
knee osteoarthritis. However it appears that the use of a single spinning technique, a platelet concentration lower than 5 times the
baseline, and avoidance of leukocytes should be preferred.
1. Introduction
Knee osteoarthritis (OA) is one of the major causes of pain
and physical disability in older adults. Symptomatic knee
OA occurs in approximately 13% of people who are aged
≥60 years old [1, 2]. It is a clinical syndrome of joint pain
with multifactorial etiopathogenesis that is characterized by
the gradual loss of articular cartilage, osteophyte formation,
subchondral bone remodeling, and inflammation of the joint
[3]. Radiographic kneeOA incidence inwomen≥55 yearswas
estimated at 2.5% per year [1].
Different methods are used to alleviate the symptoms
of patients with knee OA, including analgesics, physical
therapy, exercise prescription, and intra-articular injections,
such as corticosteroids injection and hyaluronic acid (HA)
[4, 5]. Owing to the limited lifespan of joint replacements
with implant wear and the associated risk for joint revision,
conservative treatment modalities are the central focus in the
younger and middle-aged population with cartilage damage
and OA of the knee [6].
The management of chondral disease is challenging
because of its inherent low healing potential. In fact, the
regeneration ability of cartilage is limited due to its isolation
from systemic regulation and its lack of vessels and nerves
[7, 8].
New studies have focused on modern therapeutic meth-
ods that stimulate cartilage healing process and improve the
damage, including the use of platelet-rich plasma (PRP),
an autologous growth factor treatment [4]. PRP is prepared
from autologous blood by centrifugation to obtain a highly
concentrated sample of platelets, which is four to five times
higher than that of normal blood. The platelets undergo
degranulation to release growth factors (GFs) that promote
angiogenesis, tissue remodeling (bone, skin, muscle, tendon,
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etc.), and wound healing [9, 10]. More recently, PRP has
been used in the management of knee OA. The importance
behind using PRP in cartilage tissue engineering field is
that PRP is rich in growth factors, including those that
promote proliferation of chondrogenic cells and secretion of
cartilaginous matrix [11].
Many papers were published on PRP for knee OA,
including a lot of randomized controlled trials (RCTs)
and different systematic reviews. Due to the mixed results
from controlled studies, the clinical efficacy of PRP in the
treatment of knee OA is unclear with shortcomings in
the current literature. Indeed, there are variations in the
treatment approach including subject, knee and outcome-
specific variables, including, but not limited to PRP prepa-
rations techniques, platelet count, severity of OA, number of
injections, interval/frequency of administration, and a lack
of volume standardization [12, 13]. In addition, the use of
anticoagulants, activating agents, and separation techniques
has varied considerably among studies. Campbell et al.
published recently a systematic review ofmeta-analyses, eval-
uating platelet-rich plasma injection in the treatment of knee
joint cartilage degenerative pathology [14]. They included 3
high-quality meta-analyses. Campbell et al. emphasized that
there still remain multiple unanswered questions about the
best PRP formulation. Different classification of PRP was
proposed by various authors to organize and compare results
in the literature but remains probably incomplete considering
the number of parameters that can characterize PRP [15].
The objective of this study was to evaluate the similarities
and differences between the variety of PRP formulations,
preparation, and uses of this techniques and to try to
determine characteristics of the PRP which tend to give the
best result.
2. Methods
In November 2015, Campbell et al. published a system-
atic review of meta-analyses, evaluating platelet-rich plasma
injection in the treatment of knee OA [14]. We selected the
studies included in the 3 most recent meta-analyses [16–18]
on the topics. One RCT was excluded because it was written
inChinese [19]. Two other RCTswere added, after an updated
literature search [20, 21].
We listed the outcomes that were assessed and reported
by each study, including Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC), Visual Analog
Scale (VAS), International Knee Documentation Committee
(IKDC), and Knee Injury and Osteoarthritis Outcome Score
(KOOS).
The minimal clinically important improvement (MCII)
was defined to help determining whether an observed differ-
ence is clinically important. Tubach et al. promoted in 2012
the use of values of MCII, including knee OA, for different
outcome criteria [22].They determined a value of 15 of 100 for
absolute improvement or 20% for relative improvement. We
used Tubach et al.’s values to classify the different studies in
2 groups depending on the outcomes: bad responders group
(BRG < MCII) and very good responders group (VGRG >
2xMCII).
Table 1: The Mishra and PAW classification.
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Type 1 Increased No A: ≥5x
B: <5x
Type 2 Increased Yes A: ≥5x
B: <5x
Type 3 Minimal or no WBCs No A: ≥5x
B: <5x
Type 4 Minimal or no WBCs Yes A: ≥5x
B: <5x
The full texts were thoroughly read to extract fea-
tures of the PRP used by the various authors from the 2
groups. Features included the number of injections, time
between injections, volume of PRP, centrifugation technique,
time after blood puncture before injection, anticoagulation,
platelet/erythrocytes or red blood cells (RBC)/leukocytes or
white blood cells (WBC) concentration, platelet activation,
use of NaHCO
3
tampon, and rehabilitation after infiltration.
We contacted all of the authors by e-mail because of
insufficient data in the manuscripts.
To classify the PRP of the different studies, we used the
Mishra and PAW classifications [23, 24]. These 2 classifi-
cations allow the readers to easily know level of platelets
concentration, the presence or absence of WBC, and the
activation before injection or not (Table 1).
3. Results
A total of 19 articles were selected [20, 21, 25–41]. Five authors
(Acosta-Olivo, Jang, Patel, Say, and Vaquerizo) out of 19
(26.3%) gave us more information about the quality of the
PRP they used in their study.The outcomes that were assessed
and reported by each author are represented in Table 2. The
separation between BRG (𝑁 = 4) and VGRG (𝑁 = 7) was
made from these values. Eight studies were not included in
any group.
In 4 out 7 studies of the VGRG, 1 or 2 injections were
given, against 3 in all the studies of the BRG. Time between
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injections tends to be more important in the VGRG (2 to 3
weeks in 4 out of 5 studies with many injections in VGRG
in contrast to 1 in BRG). Volume injected varied from 2.5mL
to 8mL in the VGRG. Good results were objectified with the
same technique (Endoret), at very different volumes (from
2.5 to 8mL). Centrifugation technique was variable. Single
spinning technique was the one used most (6/11; 5/7 VGRG,
notmentioned in 2/7; 1/4 BRG, notmentioned in 1/4) and this
technique appears to give better results than double spinning
technique. Endoret was used in 3 of 7 good responders and
never in bad responders.
Time after blood puncture before injections was less than
2 hours. Freezing technique was used to conserve the PRP
units when other injections were scheduled in the following
weeks in 2 to 3 out of 11 studies (𝑁 = 2/4 in BRG, 𝑁 = 0 to
1/7 in VGRG with many injections as it was not mentioned
by Wang et al.). In other studies, blood was extracted each
time. Anticoagulation, when mentioned, with citrate (CPDA
or sodium citrate) was the only used technique (6/11) and
almost always in VGRG (5/7). Activation with CaCl
2
was
used in a lot of studies, from the 2 groups (mentioned in 4/7
studies of VGRG and 3/4 studies of BRG).
Platelet concentration was only available in 7/11 studies.
The exact value was measured in only 1 out 11 studies and the
mean value in only 1 out 11 studies (while it could have been
a very important parameter). Other authors compared the
platelet concentrations obtained using different preparation
techniques [23, 42, 43]. We reported their results to complete
the Mishra and PAW classifications. It is interesting to note
that almost all studies from the VGRG were Mishra 4B and
PAWP2B𝛽.This corresponds to an activated, leukocyte-poor
PRP, with a platelet concentration of less than 5x baseline (for
Mishra classification), or, more precisely between baseline
and 750000 platelets/𝜇L (for PAW classification) [23, 24].
The exact count of RBC and the use of NaHCO
3
were
never available.Theuse of PRPwithWBC is only found in the
BRG. There was no standardized protocol of rehabilitation
after infiltration. Most of the time (𝑁 = 6/11, 12/19),
relative rest, analgesics, no nonsteroidal anti-inflammatory
drugs (NSAIDs), and light activity were recommended, when
mentioned.
4. Discussion
We observed an important variability of the PRP preparation
technique and a major lack of standardization. Furthermore,
a lot of information is missing. However, single spinning
technique tends to give good results,more precisely the use an
activated, leukocyte-poor PRP with a platelet concentration
of less than 5x baseline. The use of CaCl
2
and citrate is
frequent. Volume of PRP is inconstant. Leukocyte-rich PRP
is only used in the BRG.
Meheux et al. tried to determine similarities and differ-
ences in outcomes based on the PRP formulations used in 6
studies [13]. All but one study used leukocyte-poor PRP and
showed good outcomes, which did not help comparing the
effects of leukocyte-rich PRP versus leukocyte-poor PRP.
We aimed to compare the different formulations of PRPs,
after selecting the good and the bad responders, including
other features and studies than Meheux et al. November
2012, Tubach et al. promoted the use of values of minimal
clinically important improvement (MCII) in reporting the
results of trials of different rheumatic diseases, including
knee OA, with pain, patient global assessment, physical
function, or physician global assessment used as outcome
criteria [22].They determined a value of 15 of 100 for absolute
improvement or 20% for relative improvement.
Only 4 trials did not reach this score, we considered them
as bad responders. All of the other studies reached this cut-
off score (𝑁 = 15/19). To be more discriminant and to select
the studies which results were really the best, we decided
to consider as very good responders the trials whose results
reached twice this score (Table 3). Seven trials were included
in this group.
After comparing the results of our analysis, we could
propose that the following criteria should be applied:
(i) To focus more on PRP preparation technique than on
volume injected, single spinning technique appears attractive,
such as PRGF-Endoret by BTI, which is used in 3 of 6 studies
fromVGRG. It consists of a simple and rapid protocol, with a
single spinning approach during 8 minutes at 1800 rpm. The
PRGF obtained by this technique should not contain WBCs
and was first defined by Anitua in 1999 [44]. However, this
technique appears to be technically imprecise and may lead
to irreproducible results because of the pipetting technique,
which is operator-dependent and poses a risk of a low
platelet collection efficiency, as platelets and leukocytes are
found together in the intermediate layer after low spin
centrifugation [15]. Filardo et al. compared safety and effi-
cacy of PRP obtained after single (PRGF) or double (PRP)
centrifugation [32]. A significant clinical improvement was
obtained in the 2 groups, although PRP injections produced
more pain and swelling. Methodological changes and lack
of reproducible protocol were emphasized by Anitua et al.
[45]. Lack of standardization of PRP preparation could have
led to changing results in the literature [23]. The only way
to have a reproducible PRP is to use an apheresis machine
[46]. In addition to this, its use decreases the potential risk
of contamination and the unavoidable variability of manual
techniques.
(ii) A platelet concentration 3 to 4 times that of whole
blood [46] is recommended for treatment of tendinopathies
with PRP. Similar concentrations appear to be recommended
for osteoarthritis in view of our results. As it was pointed by
Delong et al., this most basic measurement is still lacking in
the recent publications [23].
(iii) The presence of WBC is still much debated [23,
32, 44, 47]. Braun et al. showed that using PRP rich in
leukocytes and RBC resulted in significant synoviocytes
cell death and proinflammatory mediator productions [48].
Some authors prefer avoiding WBC in PRP because of the
potential deleterious effect of protease and reactive oxygen
released fromWBC. Others promote the preventive effect of
cytokines and enzymes against infection [32]. A preclinical
study highlighted that, in a normal equine tendon, leukocyte-
riche PRP contributes to inflammatory cytokine production,
even if isolated values of IL-1B and TNF-𝛼 were increased
compared to a leukocyte-poor PRP [47]. In our opinion,
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RBC and WBC should be avoided in PRP preparations.
Our opinion is not shared by all. A clinical study com-
pared the intra-articular injection of PRGF, which is a PRP
obtained after a single centrifugation and which contains no
WBC versus PRP obtained after double centrifugation which
contain WBC. Both treatment groups presented a similar
statistically significant improvement even if the comparative
analysis showed more swelling and pain after PRP injection
[32]. Furthermore, Mariani et al. showed no upregulation of
proinflammatorymediators after leukocyte-rich injection for
knee OA in synovial fluid or plasma [49].
(iv) As for tendinopathy treatment, it is necessary to limit
the number of injections to avoid side effects and increase
in the price of the treatment [50]. Few authors compared
the effect of one versus multiple PRP injection for knee OA.
Discordant results are available in the literature. Patel et al.
compared the effect of a single injection to 2 injections of
PRP 3 weeks apart. Short-term results (6 weeks) were similar
between the two groups. A longer follow-up (3 to 6 months)
showed that the effect tends to taper over time in the two
groups [26]. More recent studies demonstrated beneficial
effects of multiple injections. Go¨rmeli et al. showed better
results after 3 injections against a single injection for early
knee OA after 6 months. For advanced OA, no difference was
found [51]. In our daily practice, we realize a total number of
2 injections, as suggested by Kavadar et al. who compared the
effects of a single injection, 2 injections, or 3 injections of PRP
in moderate knee OA [52]. Future comparative multicentric
RCTs on this topic with long term follow-up period should
be realized to bring out the most effective injection number.
(v) Injection interval is of 2 to 3 weeks.
(vi) Freezing technique could lead to damage of the PRP
product [45]. Sonker andDubey showed a steep fall in growth
factor levels after 5 days of storage after a preparation applying
the double freeze thaw technique for the growth factor release
[53]. This appears confirmed by our study, because only
studies from the BRG (2/4) used this technique to preserve
the PRP for further injections. Even if a good clinical efficacy
is obtained in studies with PRP stored by freezing [32],
it is possible that even better results were obtained with
nonfrozen PRP. Note that one author of the VGRG did not
mention whether this technique was used or not [37]. The
use of an anticoagulant is necessary, citrate is recommended
as it preserves platelet reactivity, compared to EDTA and
heparin [46]. No difference appears between sodium citrate
and citrate dextrose [54].
Even if some authors gave us an answer, some features
were not available, because they were not measured and
are missing in our comparison table. Platelet concentration,
presence or absence of red or white blood cells and its
concentration, and use of tampon NaHCO
3
were rarely, if
ever mentioned. This information should be mentioned in
future studies to help determine which PRPs tend to give
the best results for osteoarthritis, preferably using a peer
reviewed classification system, such as PAW and Mishra
classification.
In the literature, other recommendations are described.
PRP should be prepared as soon as possible after blood
collection, to avoid undesired platelet activation [46]. It
is recommended activating platelets by adding CaCl
2
[43]
and a basic substance like NaHCO
3
to get a pH greater
than 8.0 that stimulates platelet activation [46]. Double
freeze thaw technique was compared to CaCl
2
as a growth
factor concentration technique [53]. Levels of PDGF-AB and
PDGF-BB were significantly higher with CaCl
2
technique
whereas there was a nonsignificant trend to higher levels of
TGF-𝛽1 and IGF-1 with double-thaw technique. The exact
platelet count and RBC and WBC count are still unknown.
The potential effect of the volume of PRP also has to be
considered [55].
A standardization of PRP preparation technique and the
use of a reproducible technique would be of great help to
interpret and compare the results of the numerous studies,
to secondarily bring out the characteristics of the PRP which
gives the best results. This current lack and important vari-
ability of PRP make this task in time confusing. The degree
of knee OA also influences the efficacy of PRP injection and
duration of symptoms relief. Better results are achieved in
young patients with a little cartilage degeneration [14, 17, 32].
Kon et al. compared the efficacy of PRP injection in patients
affected by cartilage degenerative lesions and early and severe
knee OA. Better results were achieved in younger patients
with a low degree of cartilage degeneration [33].
Limitations of our study are the following. We did not
perform a new systematic review of the literature, because
many recentmeta-analyses are available.We did not compare
the studies’ methodology, which is very miscellaneous. We
arbitrarily decided to be more discriminant in using the cut-
off score of twice the MCII value promoted by Tubach et al.
to define the very good responders.
5. Conclusion
There is a lack of standardization in PRP preparation tech-
nique. Our study helped identify features of PRP recom-
mended for knee OA treatment, such as the use of a single
spinning technique, a platelet concentration lower than 5
times the baseline (from 3 to 4), and avoiding RBC andWBC.
We recommend leveraging this information about PRP for
future studies.
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